Richard Casaburi
Pulmonary Disease · Torrance, CANPI 1639149289
Payments from drug & device makers
Across 184 payments — averaging $1221.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$126K
- Boehringer Ingelheim$23K
- Boehringer Ingelheim International GmbH$21K
- Genentech, Inc.$19K
- Regeneron$9K
- Inogen, Inc.$8K
- plus $19K from 8 others
Across 2 payments — averaging $1063.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$65,86832%
- Speaking & faculty fees$115,46455%
- Travel & lodging$23,05611%
- Food & beverage$3,6942%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 138 | $125,559 |
| Boehringer Ingelheim | 5 | $22,686 |
| Boehringer Ingelheim International GmbH | 7 | $21,324 |
| Genentech, Inc. | 6 | $19,181 |
| Regeneron | 2 | $9,113 |
| Inogen, Inc. | 4 | $8,247 |
| Viiv Healthcare Company | 3 | $6,556 |
| AstraZeneca | 11 | $5,706 |
| Abbott | 3 | $5,600 |
| Boehringer Ingelheim Taiwan Ltd. | 1 | $520 |
| Verona Pharma, Inc. | 1 | $107 |
| Cleerly, Inc. | 1 | $56 |
| Pfizer | 1 | $19 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$82,796
- XOLAIR$15,261
- ANORO$13,838
- DUPIXENT$9,113
- INOGEN$6,768
- FreeStyle Libre Pro$5,600
- FASENRA$4,890
- STIOLTO$4,726
- Avastin$3,920
- Herceptin$3,920
- Lucentis$3,920
- Rituxan$3,920
- Tamiflu$3,920
- STIOLTO RESPIMAT$3,898
- NUCALA$3,250
- SPIRIVA$2,600
- SPIRIVA RESPIMAT$1,500
- InogenOne$1,478
- ANORO ELLIPTA$1,200
- SYMBICORT$600
How this compares
$224,687 in reported general payments places this provider in the 90th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Torrance
- William StringerTorrance$1M
- Catherine ObergTorrance$457K
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.